Our Products
Our product is the world’s first approved microbiome-based therapy for the treatment of recurrent and refractory Clostridioides difficile infection.
An Overview
The product is manufactured in a purpose built Australian GMP facility, following rigorous and quality-controlled screening, and manufacturing processes. It is currently supplied to hospitals and clinics throughout Australia and can be administered by healthcare professionals.
MEDIA RELEASE
BiomeBank announces world first regulatory approval for donor derived microbiome drug
The Evidence
Donor derived Faecal Microbiota Transplantation (FMT) is a highly effective therapy for the treatment of C.difficle infection; the most common cause of health care associated diarrhoea. Multiple randomised controlled trials and meta-analyses of these studies have demonstrated the superiority of FMT over antibiotic therapy alone for the treatment of recurrent C.difficile infection.
While FMT is now the standard of care for recurrent C.difficile infection in most international guidelines, evidence is emerging for its use in other diseases. BiomeBank’s co-founders Dr Sam Costello and Dr Rob Bryant have been pioneers in this field and BiomeBank is facilitating a number of clinical trials in a range of diseases with collaborating organisations.
Current Treatment (Antibiotics) vs Faecal Microbial Transplantation (FMT)
Antibiotic Treatment
FMT
OUR PRODUCTS ARE ONLY AVAILABLE FOR SALE TO MEDICAL PRACTITIONERS.
To access further information or order our therapies please fill in your details below.